相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。PCSK9 (Proprotein Convertase Subtilisin/Kexin 9) Enhances Platelet Activation, Thrombosis, and Myocardial Infarct Expansion by Binding to Platelet CD36
Zhiyong Qi et al.
CIRCULATION (2021)
Association Between Circulating Proprotein Convertase Subtilisin/Kexin Type 9 and Major Adverse Cardiovascular Events, Stroke, and All-Cause Mortality: Systemic Review and Meta-Analysis
Yimo Zhou et al.
FRONTIERS IN CARDIOVASCULAR MEDICINE (2021)
Clinical Implications of Monogenic Versus Polygenic Hypercholesterolemia: Long-Term Response to Treatment, Coronary Atherosclerosis Burden, and Cardiovascular Events
Laura D'Erasmo et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2021)
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)
Francois Mach et al.
EUROPEAN HEART JOURNAL (2020)
Platelet function and activation markers in primary hypercholesterolemia treated with anti-PCSK9 monoclonal antibody: A 12-month follow-up
Cristina Barale et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2020)
Arterial stiffness improvement after adding on PCSK9 inhibitors or ezetimibe to high-intensity statins in patients with familial hypercholesterolemia: A Two-Lipid Center Real-World Experience
Giuseppe Mandraffino et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2020)
A novel role of MMP2 in regulating platelet NOX2 activation
Cristina Nocella et al.
FREE RADICAL BIOLOGY AND MEDICINE (2020)
Plasma kinetics of mature PCSK9, furin-cleaved PCSK9, and Lp(a) with or without administration of PCSK9 inhibitors in acute myocardial infarction
Akihiro Nakamura et al.
JOURNAL OF CARDIOLOGY (2020)
PCSK9 Regulates Nox2-Mediated Platelet Activation via CD36 Receptor in Patients with Atrial Fibrillation
Vittoria Cammisotto et al.
ANTIOXIDANTS (2020)
Poor Adherence to Mediterranean Diet and Serum Lipopolysaccharide Are Associated with Oxidative Stress in Patients with Non-Alcoholic Fatty Liver Disease
Francesco Baratta et al.
NUTRIENTS (2020)
Interplay between Nox2 Activity and Platelet Activation in Patients with Sepsis and Septic Shock: A Prospective Study
Giusy Tiseo et al.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2020)
Effect of Evolocumab on Lipoprotein(a) and PCSK9 in Healthy Individuals with Elevated Lipoprotein(a) Level
Olga Afanasieva et al.
JOURNAL OF CARDIOVASCULAR DEVELOPMENT AND DISEASE (2020)
A phenome-wide association study to discover pleiotropic effects of PCSK9, APOB, and LDLR
Maya S. Safarova et al.
NPJ GENOMIC MEDICINE (2019)
Does the Coexistence of Chronic Obstructive Pulmonary Disease and Atrial Fibrillation Affect Nox2 Activity and Urinary Isoprostanes Excretion?
Daniele Pastori et al.
ANTIOXIDANTS & REDOX SIGNALING (2019)
Effect of Alirocumab on Coronary Atheroma Volume in Japanese Patients With Acute Coronary Syndrome - The ODYSSEY J-IVUS Trial
Junya Ako et al.
CIRCULATION JOURNAL (2019)
PCSK9 in Haemostasis and Thrombosis: Possible Pleiotropic Effects of PCSK9 Inhibitors in Cardiovascular Prevention
Francesco Paciullo et al.
THROMBOSIS AND HAEMOSTASIS (2019)
Diagnosing Resistance to a Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor
Michael D. Shapiro et al.
ANNALS OF INTERNAL MEDICINE (2018)
Oleuropein, a component of extra virgin olive oil, lowers postprandial glycaemia in healthy subjects
Roberto Carnevale et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2018)
Pleiotropic effects of proprotein convertase subtilisin/kexin type 9 inhibitors?
Theodosios D. Filippatos et al.
CURRENT OPINION IN LIPIDOLOGY (2018)
PCSK9 as a Positive Modulator of Platelet Activation
Marina Camera et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Evaluation of the performance of Dutch Lipid Clinic Network score in an Italian FH population: The LIPIGEN study
Manuela Casula et al.
ATHEROSCLEROSIS (2018)
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
G. G. Schwartz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Relationship of PCSK9 and Urinary Thromboxane Excretion to Cardiovascular Events in Patients With Atrial Fibrillation
Daniele Pastori et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Marc S. Sabatine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Association Between Circulating Baseline Proprotein Convertase Subtilisin Kexin Type 9 Levels and Efficacy of Evolocumab
Nihar R. Desai et al.
JAMA CARDIOLOGY (2017)
Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients The GLAGOV Randomized Clinical Trial
Stephen J. Nicholls et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
CD36 Binds Oxidized Low Density Lipoprotein (LDL) in a Mechanism Dependent upon Fatty Acid Binding
Anthony G. Jay et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
LDL oxidation by platelets propagates platelet activation via an oxidative stress-mediated mechanism
Roberto Carnevale et al.
ATHEROSCLEROSIS (2014)
Effect of Evolocumab or Ezetimibe Added to Moderate- or High-Intensity Statin Therapy on LDL-C Lowering in Patients With Hypercholesterolemia The LAPLACE-2 Randomized Clinical Trial
Jennifer G. Robinson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease
Borge G. Nordestgaard et al.
EUROPEAN HEART JOURNAL (2013)
PI3Kγ inhibition reduces blood pressure by a vasorelaxant Akt/L-type calcium channel mechanism
Daniela Carnevale et al.
CARDIOVASCULAR RESEARCH (2012)
NADPH oxidase inhibitors: a decade of discovery from Nox2ds to HTS
Eugenia Cifuentes-Pagano et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2012)
Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin Therapy
James M. McKenney et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial
Evan A. Stein et al.
LANCET (2012)
Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype
Eugene A. Podrez et al.
NATURE MEDICINE (2007)
The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population
Amanda J. Hooper et al.
ATHEROSCLEROSIS (2007)
Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice
Thomas A. Lagace et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Elevated concentrations of exhaled hydrogen peroxide in asthmatic patients
A Emelyanov et al.
CHEST (2001)
分享论文
